Published in Clin J Am Soc Nephrol on October 10, 2007
The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant (2012) 1.73
Elevated expression levels of ANXA11, integrins β3 and α3, and TNF-α contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin Appl (2011) 0.89
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med (2006) 3.57
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis (2008) 2.54
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood (2011) 2.41
Donor kidney exchanges. Am J Transplant (2004) 2.39
Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int (2004) 2.16
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol (2002) 1.98
Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A (2008) 1.82
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog (2009) 1.81
Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol (2004) 1.72
Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes (2008) 1.63
Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors. Transplantation (2004) 1.59
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation (2013) 1.50
Complete genome sequence of a tenth human polyomavirus. J Virol (2012) 1.48
Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol (2006) 1.44
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol (2007) 1.31
Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes (2010) 1.24
CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection. Trends Immunol (2006) 1.20
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol (2013) 1.20
Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol (2004) 1.19
A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes (2010) 1.18
The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg (2010) 1.12
A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol (2007) 1.12
Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med (2012) 1.10
The mobilization and effect of endogenous bone marrow progenitor cells in diabetic wound healing. Cell Transplant (2010) 1.08
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol (2010) 1.04
Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol (2010) 1.04
Characterization of donor dendritic cells and enhancement of dendritic cell efflux with CC-chemokine ligand 21: a novel strategy to prolong islet allograft survival. Diabetes (2007) 1.04
Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol (2008) 1.02
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation (2012) 1.01
Racial and ethnic disparities in kidney transplantation. Transpl Int (2010) 1.00
Incentives for organ donation: proposed standards for an internationally acceptable system. Am J Transplant (2011) 0.99
Kidney allocation and the aging immune response. N Engl J Med (2011) 0.97
Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circ Res (2011) 0.96
Phenotypic and functional differences between wild-type and CCR2-/- dendritic cells: implications for islet transplantation. Transplantation (2008) 0.96
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation (2015) 0.96
WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood (2012) 0.96
Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J (2010) 0.94
Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int (2012) 0.94
Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94
Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J Am Soc Nephrol (2003) 0.94
Immunological aspects of pancreatic islet cell transplantation. Expert Rev Clin Immunol (2010) 0.94
Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation (2011) 0.93
Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood (2010) 0.93
A divergent variant of the eleventh human polyomavirus species, saint louis polyomavirus. Genome Announc (2013) 0.92
The role of HCA2 (GPR109A) in regulating macrophage function. FASEB J (2013) 0.92
Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int (2008) 0.92
Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. Transplantation (2011) 0.91
The effect of Rho kinase inhibition on long-term keratinocyte proliferation is rapid and conditional. Stem Cell Res Ther (2014) 0.91
Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant (2005) 0.91
Metabolic and immunological features of the failing islet-transplanted patient. Diabetes Care (2007) 0.90
A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo. J Immunol (2007) 0.90
Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. J Clin Invest (2014) 0.89
Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant (2003) 0.89
Jagged2-signaling promotes IL-6-dependent transplant rejection. Eur J Immunol (2013) 0.89
Cutaneous neoplasms in renal transplant recipients. Eur J Dermatol (2002) 0.88
Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B-producing regulatory T cells. J Immunol (2013) 0.88
Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation (2012) 0.88
Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J Immunol (2006) 0.88
Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. Blood (2010) 0.87
Divergent role of donor dendritic cells in rejection versus tolerance of allografts. J Am Soc Nephrol (2009) 0.87
Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A. J Transplant (2012) 0.86
Ischemic injury enhances dendritic cell immunogenicity via TLR4 and NF-kappa B activation. J Immunol (2010) 0.86
Iranian staff nurses' attitudes toward nursing students. Nurse Educ Today (2010) 0.85
The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. J Immunol (2011) 0.84
Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando) (2011) 0.84
The renin-angiotensin system: an old, newly discovered player in immunoregulation. Transplant Rev (Orlando) (2009) 0.84
Importance of donor- and recipient-derived selectins in cardiac allograft rejection. J Am Soc Nephrol (2007) 0.84
Using a neural network with flow cytometry histograms to recognize cell surface protein binding patterns. Proc AMIA Symp (2002) 0.83
Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy. Acta Diabetol (2014) 0.83